Phaseline

Companies › TCRx Therapeutics Co.Ltd

TCRx Therapeutics Co.Ltd: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KXV01 TCR Lentinvivo Injection
Lentivirus vector delivering personalized tumor-reactive TCR for engineered T-cell therapy
–Phase 1Advanced Solid Tumors; Advanced Solid CancerDec 2026
KSV01 Injection
CD19-targeted CAR-T cell therapy using lentiviral vector
CD19Phase 1Non-Hodgkin Lymphoma; B-ALLDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07275853KXV01 TCR Lentinvivo InjectionPhase 1Advanced Solid TumorsOncologyDec 2026
NCT07196579KXV01 TCR Lentinvivo InjectionPhase 1Advanced Solid CancerOncologyDec 2026
NCT07246707KSV01 InjectionPhase 1B-ALLOncologyOct 2027
NCT07596693KXV01 TCR Lentinvivo InjectionPhase 1Advanced Solid TumorsOncologyDec 2027
NCT07260812KSV01 InjectionPhase 1Non-Hodgkin LymphomaOncologyDec 2028

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.